Cyclopamine

Catalog No.S1146 Synonyms: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

    (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

  • (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

    For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets
Smoothened [1]
(TM3Hh12 cells)
46 nM
In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 NYTpVYpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWm4dZlVUUN3ME21Mlg3PjZizszN NX\Hb5B[W0GQR1XS
DOHH-2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTlwM{W2PFkh|ryP NXnyfXVVW0GQR1XS
no-10 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEL4TodKSzVyPUmuPVA{QSEQvF2= NEHXS3pUSU6JRWK=
LS-513 MmLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHjRXFKSzVyPUGxMlM2PDdizszN M1fx[nNCVkeHUh?=
ALL-PO M1zKUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHCRYV5UUN3ME2xNU44PzN2IN88US=> MnXUV2FPT0WU
8-MG-BA MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrBTWM2OD1zMz6xNVI{KM7:TR?= NF32S4RUSU6JRWK=
RPMI-8402 MkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFm3[|NKSzVyPUG1Mlg2OzdizszN NVjSRYlFW0GQR1XS
EoL-1-cell NVvBc3M5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;LUmlEPTB;MUiuOVk1QCEQvF2= NETQd4tUSU6JRWK=
NALM-6 Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1i0T2lEPTB;MUmuNFE3PyEQvF2= MW\TRW5ITVJ?
DEL MkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jESWlEPTB;MkCuNVQ4OSEQvF2= MYfTRW5ITVJ?
SR NWXzNXYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELDVGpKSzVyPUKzMlY4OTVizszN M2rXRnNCVkeHUh?=
697 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPOTWM2OD1{Nj62NVU2KM7:TR?= MXvTRW5ITVJ?
COLO-829 M1PvOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfJNoVNUUN3ME2yOk45PDh|IN88US=> MX3TRW5ITVJ?
EVSA-T MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoKwTWM2OD1{Nz61OVYyKM7:TR?= M2H2PHNCVkeHUh?=
ATN-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLBNY9zUUN3ME2zNU4zOzJ7IN88US=> NF;0dG9USU6JRWK=
L-363 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\3V4hKSzVyPUOxMlc1PjFizszN NF23WVhUSU6JRWK=
LAMA-84 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHWTWM2OD1|Mj61NlEyKM7:TR?= NYS0dJg3W0GQR1XS
NOS-1 NVTxOVM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ux[mlEPTB;M{SuNlk2PiEQvF2= Ml;KV2FPT0WU
BB30-HNC MlXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTOb4R4UUN3ME2zOE4{OzB4IN88US=> MV\TRW5ITVJ?
BC-1 NYjq[WMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPyRZpKSzVyPUO3Mlk4PDZizszN NGfWPY5USU6JRWK=
IST-SL2 MnO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLIT4dKSzVyPUO4MlIzPCEQvF2= M33D[nNCVkeHUh?=
D-392MG M4nOU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkWzTWM2OD12MD6yNlE2KM7:TR?= MYTTRW5ITVJ?
no-11 NWLWc4g{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH21[ZBKSzVyPUSwMlU2OjFizszN NWKyfnB5W0GQR1XS
LC4-1 NETwVWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTRyLki3NVYh|ryP MXjTRW5ITVJ?
A388 MlntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjN[nR{UUN3ME20Nk42QDR6IN88US=> NHjud4VUSU6JRWK=
NTERA-S-cl-D1 M3O2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXGTWM2OD12Mj63NFc1KM7:TR?= M2PQeXNCVkeHUh?=
CESS MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXWb2pKSzVyPUS0MlIzOzJizszN M4H2[HNCVkeHUh?=
RS4-11 Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrQTWM2OD12OT6wPVM5KM7:TR?= MUPTRW5ITVJ?
MS-1 MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULiRoJ7UUN3ME21NE46OzVzIN88US=> MojvV2FPT0WU
CTV-1 NVr3WnNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTBVHJKSzVyPUWxMlA4PCEQvF2= MU\TRW5ITVJ?
D-502MG MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLkUo1KSzVyPUWxMlYzPzFizszN M1P5fnNCVkeHUh?=
ML-2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTV{LkmxPVUh|ryP MYXTRW5ITVJ?
SK-NEP-1 MmT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDn[FhQUUN3ME21N{4{QTJ|IN88US=> NInqPZNUSU6JRWK=
LOXIMVI M2XSS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7Jc45KSzVyPUWzMlU5QDRizszN M2q5c3NCVkeHUh?=
DJM-1 MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DpXGlEPTB;NU[uN|M6OSEQvF2= M3XpO3NCVkeHUh?=
GI-1 MoC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTV4Lk[xOFkh|ryP M{DHfXNCVkeHUh?=
IST-MES1 NI\KZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TY[GlEPTB;NkCuOVQ6OyEQvF2= NVHiWpp{W0GQR1XS
MV-4-11 NFWwSJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHBVGtKSzVyPU[wMlY2OzhizszN MYPTRW5ITVJ?
OVCAR-4 MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTZ|LkW2OVch|ryP NHKwUnBUSU6JRWK=
KE-37 NEfzd4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFX4c|ZKSzVyPU[2MlI3PjhizszN M1zSWHNCVkeHUh?=
D-542MG NEjiNmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGT6dYlKSzVyPU[4MlQyOzVizszN MnziV2FPT0WU
MHH-PREB-1 M17ycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn24TWM2OD15Mj64OFQyKM7:TR?= MXrTRW5ITVJ?
MRK-nu-1 NHTkOnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrJW3JHUUN3ME23N{41PzB3IN88US=> NYTmWpR5W0GQR1XS
D-247MG MmrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\KeHJKUUN3ME23N{42PDR{IN88US=> M1rBZXNCVkeHUh?=
OCI-AML2 NEPQS3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnG[JU5UUN3ME23Ok46OzZ7IN88US=> MVHTRW5ITVJ?
LP-1 NFz6Rm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrDV3lDUUN3ME24Nk45PzNzIN88US=> Mn25V2FPT0WU
HCC1599 M4XaNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTh2LkK4N|ch|ryP M1jpZXNCVkeHUh?=
KARPAS-45 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWi5PZV5UUN3ME24OE43QTl{IN88US=> NWfrXI9LW0GQR1XS
BE-13 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPEV2hkUUN3ME25PU4xPDd5IN88US=> MmPMV2FPT0WU
GCIY M4L2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3uzU2lEPTB;OUmuNFk2PCEQvF2= MWLTRW5ITVJ?
BV-173 NGnZeGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTFyMD6zNlUh|ryP MXPTRW5ITVJ?
LB2518-MEL NVjwPJBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTFyMD63PFkh|ryP NGHpPIZUSU6JRWK=
KS-1 Mn3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XlZWlEPTB;MUCxMlY{QSEQvF2= MYjTRW5ITVJ?
MOLT-16 MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2C2PGlEPTB;MUC0Mlk5PiEQvF2= MV7TRW5ITVJ?
NCI-H1770 NHHQd4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfzTWM2OD1zMEiuO|g1KM7:TR?= MUfTRW5ITVJ?
NCI-H82 NYfYRY0zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHte4RKSzVyPUGxNE46PzZizszN MlPDV2FPT0WU
NCCIT NIL0UI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTFzMj61Nlkh|ryP MYTTRW5ITVJ?
KALS-1 M4\2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXiVVlRUUN3ME2xNVUvQTRzIN88US=> M2ixcHNCVkeHUh?=
LB2241-RCC NV;UPHBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTqNFZFUUN3ME2xNVYvPjd7IN88US=> Mmf3V2FPT0WU
HH NF\TbY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLoNpFKSzVyPUGxO{4{QTVizszN MoT4V2FPT0WU
HD-MY-Z MmfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFzOD60PFgh|ryP NFS3ZoZUSU6JRWK=
EB-3 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HZ[GlEPTB;MUKzMlA6PCEQvF2= MXLTRW5ITVJ?
BL-70 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHy5eodKSzVyPUGyN{4yOjdizszN NYfGSWhDW0GQR1XS
K-562 NITaOFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPzXI5NUUN3ME2xNlYvOjR3IN88US=> MonuV2FPT0WU
HT-144 NGjYeVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\CPJlKSzVyPUGzN{4yPjRizszN MlzvV2FPT0WU
PF-382 NYTSOGhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHUTWM2OD1zM{SuN|YyKM7:TR?= NFjVTmZUSU6JRWK=
RPMI-8226 MmriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTF|NT6wOFUh|ryP NIPWcZhUSU6JRWK=
NCI-H1355 NYWxVFBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q2[2lEPTB;MUO1MlU5PyEQvF2= Ml3OV2FPT0WU
LXF-289 NYflfJY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLyTWM2OD1zM{muO|gyKM7:TR?= MVjTRW5ITVJ?
NCI-H69 NXf6PJhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTF2Mj65N|Ih|ryP M4LWPXNCVkeHUh?=
SK-MEL-1 MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmm3TWM2OD1zNEeuNVMh|ryP MYHTRW5ITVJ?
KARPAS-299 M2n4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTF2OT6xNkDPxE1? NXTjXFBTW0GQR1XS
GB-1 M{PHV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fIPGlEPTB;MUS5MlMzOiEQvF2= NH:2NVlUSU6JRWK=
CMK NF;oUJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXJNGNKSzVyPUG0PU42OTVizszN NGH3W3VUSU6JRWK=
MPP-89 M4LFOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvtVnpRUUN3ME2xOVYvODN3IN88US=> NIjVVXlUSU6JRWK=
KU812 NYnHUmk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIL3OY9KSzVyPUG2NU46ODJizszN MV\TRW5ITVJ?
REH NGjmS5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPBRllKSzVyPUG2Nk4yOjVizszN NFLoXY1USU6JRWK=
NEC8 NGewVJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\xTWM2OD1zNkWuNFI3KM7:TR?= NVH4Nm1WW0GQR1XS
KP-N-YS NGnoc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XFeWlEPTB;MU[4MlM6PSEQvF2= Mo\jV2FPT0WU
Ramos-2G6-4C10 MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q3dGlEPTB;MU[5MlkyPSEQvF2= M2XIT3NCVkeHUh?=
Becker NEnVOllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TjTWlEPTB;MUe0MlE5KM7:TR?= NIjVbVNUSU6JRWK=
LB647-SCLC MkLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjlNphKSzVyPUG3OU45PDVizszN MWHTRW5ITVJ?
LU-139 NXzIZZRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV6ycpFZUUN3ME2xO|gvODF7IN88US=> NVT0VVdzW0GQR1XS
QIMR-WIL NEPJS3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvpOm1oUUN3ME2xO|kvPjR4IN88US=> NXWyXphXW0GQR1XS
NCI-H1395 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnBdXhUUUN3ME2xO|kvQTl4IN88US=> NX6yW29{W0GQR1XS
NOMO-1 MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTF6Mj64OUDPxE1? NGrvOnZUSU6JRWK=
GI-ME-N NGXsUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHoTWM2OD1zOEeuPVY6KM7:TR?= MXHTRW5ITVJ?
KMS-12-PE M2L0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF6OT6yO|Mh|ryP MmL5V2FPT0WU
Daudi NWCxSlg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTF7MT6xNlgh|ryP MYHTRW5ITVJ?
LB996-RCC Mn7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDGTWM2OD1zOUGuOlk6KM7:TR?= MYfTRW5ITVJ?
NCI-H2107 NIfz[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHCVo9xUUN3ME2xPVMvPzN7IN88US=> NF;ZZmpUSU6JRWK=
SK-PN-DW MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTF7ND63NVkh|ryP NU\2N2syW0GQR1XS
MC-CAR MnL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TRSWlEPTB;MkCyMlI2OyEQvF2= M2[1VHNCVkeHUh?=
SNB75 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTJ{MT65OEDPxE1? MUDTRW5ITVJ?
ES4 NFPGXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\OTWM2OD1{MkOuO|g{KM7:TR?= NVXCSZhWW0GQR1XS
KARPAS-422 M3zuS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXTZVNKSzVyPUKyPE4{PTJizszN NU\Dfpg1W0GQR1XS
NCI-H1648 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJ{OT60PFkh|ryP NEXPNnRUSU6JRWK=
ES6 NFWyNVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrJdo5KSzVyPUKzPU41OyEQvF2= MkXQV2FPT0WU
KNS-81-FD MnHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L0VWlEPTB;MkSxMlE6PyEQvF2= NXjIRpNMW0GQR1XS
JAR M1nZWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17sSmlEPTB;MkW2MlIzPSEQvF2= MmfnV2FPT0WU
NB1 NETwW5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXNW5VmUUN3ME2yOlAvPTF4IN88US=> NX;TT4hZW0GQR1XS
D-336MG NV:3RWVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LDTGlEPTB;Mk[wMlY6QCEQvF2= MnfoV2FPT0WU
BC-3 MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTJ4NT6xO|gh|ryP MYTTRW5ITVJ?
HCC2218 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLWTWM2OD1{Nk[uOFE2KM7:TR?= Mn3QV2FPT0WU
TE-9 NIHkSY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTJ4Nj62Nlch|ryP M2PjSHNCVkeHUh?=
LB1047-RCC MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzIfWJIUUN3ME2yOlYvPzV|IN88US=> MWDTRW5ITVJ?
CTB-1 MkLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYruNoVbUUN3ME2yOlkvQTd|IN88US=> NYq0cI12W0GQR1XS
NB7 Mn3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTJ5MTFOwG0> MXzTRW5ITVJ?
ST486 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTJ5Nz60NVIh|ryP MoCzV2FPT0WU
HCC1187 M37WPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTJ6Mj64NVEh|ryP NGfSc41USU6JRWK=
NCI-SNU-16 NYfLU|F6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTJ6ND6yOFgh|ryP NIKyfWtUSU6JRWK=
COR-L279 Mnz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJ7MT61PFQh|ryP MX\TRW5ITVJ?
ES8 MnL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f5eWlEPTB;Mkm0MlE5OiEQvF2= M{LqfnNCVkeHUh?=
U-698-M MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLYTWM2OD1{OUiuNlQ{KM7:TR?= M1m5NXNCVkeHUh?=
HEL M1LBfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XhbGlEPTB;M{C5MlE1QSEQvF2= MX7TRW5ITVJ?
KINGS-1 NIji[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\aXXZKSzVyPUOxNE43PzRizszN M1jFUXNCVkeHUh?=
KY821 Mom3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnOTXZmUUN3ME2zN|YvPTl3IN88US=> NXrUfVZzW0GQR1XS
MZ1-PC MnXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzpb41KSzVyPUO0OU43OThizszN M1f5enNCVkeHUh?=
LS-411N M3TLbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXS5VYRnUUN3ME2zOVQvPjZizszN M3;2c3NCVkeHUh?=
SIG-M5 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnOzTWM2OD1|NUmuO|gzKM7:TR?= MoL5V2FPT0WU
HT MmXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPrUXNKSzVyPUO2O{44OTFizszN Ml\KV2FPT0WU
HC-1 NXLBe2toT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnDWoREUUN3ME2zOlcvPzh5IN88US=> MlXJV2FPT0WU
NCI-H1694 MnrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknJTWM2OD1|N{KuPVM1KM7:TR?= NY\MboFvW0GQR1XS
BB65-RCC NXvUW2lmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3OzSmlEPTB;M{e2MlI1PSEQvF2= MXPTRW5ITVJ?
HAL-01 NFP3T5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTN5OT64N|gh|ryP MXLTRW5ITVJ?
ARH-77 M3;iRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7xU2NJUUN3ME2zPVQvODB6IN88US=> MXjTRW5ITVJ?
MZ7-mel MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTN7Nz6yN|Mh|ryP NEDicnFUSU6JRWK=
SIMA MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLy[2ZFUUN3ME20NFMvQTN|IN88US=> MnrDV2FPT0WU
DG-75 NWDLNpdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XWfWlEPTB;NEG1MlY6QCEQvF2= NVL4dndjW0GQR1XS
HUTU-80 NUT5[2gzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXzeZV5UUN3ME20NVkvOTh3IN88US=> NWTJeY44W0GQR1XS
KNS-42 NEDIRVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTR{NT64NVUh|ryP MWXTRW5ITVJ?
SH-4 MnzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjJTWM2OD12MkeuOVY2KM7:TR?= MnXuV2FPT0WU
L-540 NX;IVlZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LYfGlEPTB;NEOxMlA{OSEQvF2= M1LDVXNCVkeHUh?=
NB10 M{DxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTR2MT6yN|Qh|ryP M2[3THNCVkeHUh?=
ES1 NEPtfmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jTcWlEPTB;NEWyMlc2OyEQvF2= M1\BWnNCVkeHUh?=
KMOE-2 MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Hp[mlEPTB;NEW2MlcyOSEQvF2= MUnTRW5ITVJ?
MC116 M2O2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7nWJBKSzVyPUS1PE4yOTZizszN MkfmV2FPT0WU
RCC10RGB NIrY[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTR4MD6wNFUh|ryP MWjTRW5ITVJ?
RL95-2 M4n1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPKdXk5UUN3ME20OlAvOjN5IN88US=> MmjiV2FPT0WU
Raji MlfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXr5[Gd[UUN3ME20OlgvOTR|IN88US=> MoXqV2FPT0WU
CAS-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn62TWM2OD12N{KuNFc{KM7:TR?= NI\Bb|FUSU6JRWK=
Calu-6 M3TxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk[3TWM2OD12N{WuNlY2KM7:TR?= NYTVSpJDW0GQR1XS
KG-1 MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHmTWM2OD12N{iuOFQh|ryP NXnLUIpxW0GQR1XS
LB771-HNC MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XYRWlEPTB;NEiyMlI{OiEQvF2= NYn4S|doW0GQR1XS
ACN MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTR7Mz61PVkh|ryP NFn5WIhUSU6JRWK=
KM12 M3K2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTR7Nj61PFkh|ryP NH7j[3dUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

Protocol

Kinase Assay:[1]
+ Expand

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:[2]
+ Expand
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • Concentrations: Dissolved in DMSO, final concentration 3 μM
  • Incubation Time: 4 days
  • Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 50 mg/kg/day
  • Administration: Subcutaneous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble
In vivo Add solvents to the product individually and in order:
10% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
1mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 411.62
Formula

C27H41NO2

CAS No. 4449-51-8
Storage powder
Synonyms 11-deoxojervine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo use in mice?

  • Answer:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID